Computations for group sequential boundaries using the Lan-DeMets spending function method

被引:80
作者
Reboussin, DM [1 ]
DeMets, DL
Kim, K
Lan, KKG
机构
[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA
[2] Univ Wisconsin, Sch Med, Dept Biostat, Madison, WI USA
[3] Pfizer Inc, Div Clin Res, Groton, CT 06340 USA
来源
CONTROLLED CLINICAL TRIALS | 2000年 / 21卷 / 03期
关键词
clinical trial; software; spending function; statistical computing; type I error;
D O I
10.1016/S0197-2456(00)00057-X
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We describe an interactive Fortran program which performs computations related to the design and analysis of group sequential clinical trials using Lan-DeMets spending functions. Many clinical trials include interim analyses of accumulating data and rely on group sequential methods to avoid consequent inflation of the type I error rate. The computations are appropriate for interim test statistics whose distribution or limiting distribution is multivariate normal with independent increments. Recent theoretical results indicate that virtually any design likely to be used in a clinical trial will fall, into this category. Interim analyses need not be equally spaced, and their number need not be specified in advance. In addition to determining sequential boundaries using an alpha spending function, the program can perform power computations, compute probabilities associated with a given set of boundaries, and generate confidence intervals. Control Clin Trials 2000;21:190-207 (C) Elsevier Science Inc. 2000.
引用
收藏
页码:190 / 207
页数:18
相关论文
共 27 条
  • [1] [Anonymous], 1971, Journal of Royal Statistical Society
  • [2] REPEATED SIGNIFICANCE TESTS ON ACCUMULATING DATA
    ARMITAGE, P
    MCPHERSO.CK
    ROWE, BC
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-GENERAL, 1969, 132 : 235 - &
  • [3] *BET BLOCK HEART A, 1982, JAMA-J AM MED ASSOC, V246, P1707
  • [4] INTERIM ANALYSIS - THE ALPHA-SPENDING FUNCTION-APPROACH
    DEMETS, DL
    LAN, KKG
    [J]. STATISTICS IN MEDICINE, 1994, 13 (13-14) : 1341 - 1352
  • [5] Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II)
    Freedman, BI
    Wuerth, JP
    Cartwright, K
    Bain, RP
    Dippe, S
    Hershon, K
    Mooradian, AD
    Spinowitz, BS
    [J]. CONTROLLED CLINICAL TRIALS, 1999, 20 (05): : 493 - 510
  • [6] GROUP SEQUENTIAL DESIGNS USING A FAMILY OF TYPE-I ERROR-PROBABILITY SPENDING FUNCTIONS
    HWANG, IK
    SHIH, WJ
    DECANI, JS
    [J]. STATISTICS IN MEDICINE, 1990, 9 (12) : 1439 - 1445
  • [7] Jennison C, 1997, J AM STAT ASSOC, V92, P1330
  • [8] Jennison C., 2000, GROUP SEQUENTIAL MET
  • [9] KIM K, 1987, BIOMETRIKA, V74, P149, DOI 10.2307/2336029
  • [10] CONFIDENCE-INTERVALS FOLLOWING GROUP SEQUENTIAL-TESTS IN CLINICAL-TRIALS
    KIM, K
    DEMETS, DL
    [J]. BIOMETRICS, 1987, 43 (04) : 857 - 864